Fig. 5.
Mobilization in CD18 hypomorphic, CD18 knockout mice, and wild-type control mice treated with anti-CD49d (VLA4).
Mice were given 3 daily injections of antibody (PS/2) at 2 mg/kg per day and bled on the fourth day. Anti-α4 treatment of CD18 hypomorphic mice increased the circulating CFU-C level about 7-fold above baseline, similar to wild-type controls (about 5-fold), whereas the same treatment of CD18 knockout mice raised the CFU-C per milliliter of blood about 49-fold above baseline.